
Today on Drug Discovery & Development
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Takeda (NYSE:TAK) has announced that in the open-label Phase 3 SPRING study, children aged 2 to 12 had 94.8% fewer hereditary angioedema (HAE) attacks during treatment with Takhzyro (lanadelumab-flyo) over 52 weeks compared to baseline. The Osaka, Japan–based company plans on presenting the data at the European Academy of Allergy and Clinical The SPRING study…Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer
Novartis (NYSE:NVS) has announced that chemotherapy plus tislelizumab, a humanized monoclonal antibody directed against PD-1, improved overall survival as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in the Phase 3 RATIONALE 306 study. The survival benefits were seen in patients regardless of PD-L1 status. The…Drug Discovery and Development See More >

Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Pfizer Inc. (NYSE:PFE) and its partner BioNTech SE (Nasdaq:BNTX) profited handsomely from COVID-19 vaccine sales in 2021. The firms raked in more than $59 billion in combined sales of the Comirnaty vaccine. The two companies have now announced a new vaccine supply agreement with the U.S. government worth $3.2 billion. Under the terms of the…
Sponsored Content See More >
Genomics/Proteomics See More >

DNA Script raises $165M Series C for DNA printing platform
DNA Script announced today that it raised $165 million in a Series C financing round, bringing its total capital raised to $280 million. South San Francisco-based DNA Script earmarked the funds raised to accelerate expansion and commercialization for the company’s Syntax benchtop nucleic acid printer and to broaden its portfolio of products powered by enzymatic…
Infectious Disease See More >

U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
Bavarian Nordic A/S (OMX:BAVA) has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has ordered an additional 2.5 million doses of liquid-frozen Jynneos vaccine. FDA first approved Jynneos, a non-replicating smallpox and monkeypox vaccine, in 2019. It continues to be the only FDA-approved vaccine indicated for monkeypox. The company will begin deliveries…
Oncology See More >

Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer
Novartis (NYSE:NVS) has announced that chemotherapy plus tislelizumab, a humanized monoclonal antibody directed against PD-1, improved overall survival as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in the Phase 3 RATIONALE 306 study. The survival benefits were seen in patients regardless of PD-L1 status. The…

Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia

Oncopeptides’ Pepaxti wins positive opinion from CHMP for multiple myeloma patients

Localizing next-generation sequencing testing for cancer patients
